Locus of control flip: management says the outcome is in its own hands, and names what it controls
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that results will be determined mainly by things the company controls, and backs it with a specific, nameable driver already real today. Let's analyze the transcript. Management discusses various challenges: tariffs, raw material costs, logistics, DIY paint softness, international softness. They talk about actions: price increases, supplier negotiations, supply chain repositioning, productivity measures. They mention specific programs: Menards rollout, Kichler acquisition, hub stores, ERP implementation. They also mention market fundamentals: demographics, home price appreciation, etc. But the question is about the coming periods: do they say results will be determined mainly by their own actions? They do say they are executing to address cost challenges and remain focused on leveraging brands, innovation, channel expertise. They also say they have a tariff task force, they are taking actions. But do they explicitly say that the future is in their own hands? They mention that they expect to grow EPS 25% despite challenges. They also talk about market fundamentals being supportive. However, the question asks: does management convey that results over coming periods will be determined mainly by things the company itself controls? They do mention specific controllable drivers: Menards program is on plan, Kichler integration, share repurchases, etc. But are they saying that the improvement will come from these? For example, they say "We're executing to address these cost challenges and remain focused on leveraging our industry-leading brands, innovation pipelines and channel expertise, and we are driving top and bottom line growth." That is a stance of self-determination. They also point to specific drivers: Menards is already rolling out, Kichler is acquired, they have a tariff task force. But the question requires that they back the stance by pointing to at least one specific, nameable driver it controls that is already real today. They mention Menards program is on plan to achieve $80 million annual run rate in Q4. That is a specific driver. Also, they mention the hub stores, but that's more of an investment. They also mention the ERP implementation as a cost, but not as a driver of improvement. They also mention the Kichler acquisition as contributing to growth. So they do have specific controllable drivers.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CLVT | Clarivate Plc | Q2 2021 | 2021-07-31 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| SXT | Sensient Technologies Corporation | Q4 2016 | 2017-02-10 | A |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| EFSC | Enterprise Financial Services Corp | Q4 2016 | 2017-01-24 | B+ |
| RPM | RPM International Inc. | Q2 2017 | 2017-01-05 | D |
| LEE | Lee Enterprises, Incorporated | Q4 2016 | 2016-12-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GIS | General Mills, Inc. | Q4 2016 | 2016-06-29 | B+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
TNET · Q1 2024 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing future results as largely self-determined through internal levers like offsetting attrition with new sales (which they expect to "consistently achieve"), disciplined execution in sales/retention/expenses, and a strategy review to align resources for profitable growth. They back this with specific, already-real drivers: 50 % YoY ACV new sales growth, 28 % YoY growth in tenured sales reps plus productivity gains, and nearly positive sequential core WSE growth in Q1. While acknowledging external headwinds (economic hiring softness, insurance cost inflation), they repeatedly redirect to what they control and point to these internal actions as the primary drivers of improvement. The stance is coherent and not generic. Answer: YES. The question requires "mainly" and "rather than by market conditions, etc."; the transcript meets that threshold by repeatedly emphasizing internal control and execution while treating external factors as secondary headwinds they are managing.
GPRO · Q4 2023 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing 2024 results as driven primarily by its own actions: the retail expansion already underway (3,200 doors added, 7,000 targeted), new product launches (four SKUs in 2024), the Forcite acquisition closed this quarter, and the Quik desktop app launched 24 hours ago. They repeatedly tie future growth to these internal levers rather than external demand or macro conditions, while noting external factors only as temporary Q4 headwinds. This meets both criteria. NO if it were mainly external or generic. YES. The stance is coherent and backed by a named, already-real driver (ret 3200 doors + strategy shift). The answer is YES. The question is answered with YES. The final answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES.
HROW · Q4 2021 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing the path ahead as substantially self-determined through its own execution and actions (e.g., "positioning Harrow Health to fulfill its vision," "executing on that vision," "we are expanding our existing commercial infrastructure," "establishing our own internal analytical lab," "we expect to see 2023 number looks like 2024, 2025" via "profits that this team has been able to generate," and "we have that amazing commercial team and we have a large customer base" for launches without dilution). They redirect from external factors like COVID to internal progress and state they will "not dilute our shareholders necessarily to launch AMP-100" due to internal capabilities.